Sector Alpha Week of 2026-07-31
Sector Alpha — machine-written from the numbers · Data as of 2026-07-31

Narayana Hrudayalaya Ltd

NH
Hospitals

Narayana Hrudayalaya Ltd's three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it.

Biggest watch item: the price is already 9 weeks into its uptrend — timing risk, not thesis risk.

The price is in a confirmed uptrend (9 weeks in) while the P/E sits at the 52nd percentile of its own 10-year range. Underneath, the last four quarters read improving — profit +5.1% year on year, and 154% of the last 3 years' profit arrived as cash. What settles it: the next one or two quarters of delivery.

Stage
Mixed
fundamental trajectory, 12 quarters
Price
₹2,029
+4.3% 1Y
P/E
48.1×
52nd pctile
of its own 10-year range
Revenue (Jun 26)
₹2,684 Cr
+78.1% YoY
Profit (Jun 26)
₹207 Cr
+5.1% YoY
Operating margin
17.0%
−5.0 pp YoY
ROCE
16%
FY26
ROIC
13.0%
vs WACC 12.0% → +1.0 pp
Cash conversion
154%
of profit, last 3 FY
01 · Price story

Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.

Narayana Hrudayalaya Ltd trades at ₹2,029, in a confirmed uptrend and 9 weeks into that stage. That is +9.6% against its own 200-day average. It sits at 97% of a 52-week range of ₹1,636 to ₹2,043. On relative strength it is currently behind the NIFTY 500 on a trailing-13-week view (2 weeks and counting).

Today the stock is in a confirmed uptrend — week 9 of stage 2, confirmed. At ₹2,029 it trades +9.6% versus its 200-day average and sits at 97% of its 52-week range (₹1,636–₹2,043).

Jul 26: ₹2,029 Weekly closing price (₹) with 50- and 200-day averages; shaded bands mark the price stage (grey base, green advance, amber top, red decline). 3-year window.
+9.6% versus the 200-day line, week 9 of stage 2
Price50-day avg200-day avg
S2S1₹2,378₹1,962₹1,546₹1,131₹715₹2,029₹1,852Jul 23May 24Feb 25Nov 25Jul 26
S2S1₹2,378₹1,962₹1,546₹1,131₹715₹2,029₹1,852Jul 23Feb 25Jul 26
Beating or trailing, week by week since 2016 Each cell is one week from 2016 to now (547 weeks): the stock's trailing 13-week return minus the NIFTY 500's, green ahead / red behind (±25% ramp). Grey cells are the 13-week warm-up or weeks where the NIFTY 500 reading is not held.
trailing 13-week return vs the NIFTY 500
Mar 16Jul 26

Against the market, two honest reads. Cumulative: over the last 10.4 years the stock moved +602% while the NIFTY 500 moved +276% — ahead of the index over the full window. Recent form: on a trailing-13-week view the stock is currently behind (2 weeks and counting; last ahead the week of 2026-07-17) — the ribbon below is that same metric, week by week.

What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.

02 · Valuation

Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.

Narayana Hrudayalaya Ltd trades at 48.1× P/E, mid-range by its own standards (52nd percentile). Its long-run median P/E is 47.0×, measured across 10.4 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.

Today's P/E of 48.1× is mid-range by its own standards (52nd percentile), against a long-run median of 47.0× measured over 10.4 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.

P/E 48.1× vs a 47.0× long-run median P/E, weekly (left axis); earnings per share, trailing twelve months, weekly (right axis). 10.4-year window; loss-period spikes above 141× shown pinned at the top. The eps (ttm) bars are red where the reading is lower than the quarter before.
mid-range by its own standards (52nd percentile)
P/EMedianEPS (TTM) (quarterly)
150.0×₹45.6117.4×₹34.284.7×₹22.852.0×₹11.419.4×₹0.0×48.10×₹42Mar 16Jul 18Dec 21Apr 24Jul 26
150.0×₹45.6117.4×₹34.284.7×₹22.852.0×₹11.419.4×₹0.0×48.10×₹42Mar 16Dec 21Jul 26
PEG 1.52 PEG ratio per quarter — the P/E divided by the earnings-growth rate. The dashed line marks 1.0: below it the growth is cheap against the multiple, above it the price already prices the growth in. Last 20 quarters.
above 1.0, the multiple already banks the growth
PEGPEG = 1.0
4.4×3.4×2.4×1.5×0.5××1.52×Q1 FY22Q1 FY23Q2 FY24Q3 FY25Q4 FY26
4.4×3.4×2.4×1.5×0.5××1.52×Q1 FY22Q2 FY24Q4 FY26
P/E
48.1×
52nd percentile of 10y
PEG
1.30
as reported

Why the multiple sits where it does: over the past year annual EPS moved +2.0% against a +4.3% price move — the price outran earnings, pushing the multiple UP its own range.

The price move, decomposed: over 5y, of the +32.9%/yr price move, ~+36.5%/yr came from earnings growth and ~−3.6 pp from the multiple (compressing); over 10y, of the +21.4%/yr price move, ~+35.1%/yr came from earnings growth and ~−13.7 pp from the multiple (compressing). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.

Put together: the multiple is unremarkable against its own past, so the story rests on the earnings line underneath it, not the multiple.

03 · Stage: Mixed

Stage: Mixed Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).

Narayana Hrudayalaya Ltd reads as mixed on its fundamental arc. Mixed — no clean majority across the growth curves, ROCE slipping at 14.5% — the per-curve reads carry the story. The read is built from 12 quarters across 4 curves, on full evidence.

Growth, year by year: revenue +44.0% in FY26, profit +1.9% Year-over-year growth per fiscal year, %: revenue (left axis); net profit and EPS (right axis — profit growth swings far wider). Zero line drawn.
Revenue YoYProfit YoYEPS YoY
49%328%31%210%13%92%−4.5%−26%−22%−145%%%44%1.9%FY16FY21FY26
49%328%31%210%13%92%−4.5%−26%−22%−145%%%44%1.9%FY16FY21FY26
Three growth curves, twelve quarters Year-on-year growth of trailing-twelve-month revenue (left axis), profit and EPS (right axis — they swing far wider), % at each quarter-end. A missing point means that reading is not held for the quarter.
the trajectory the stage is read from · revenue accelerating, profit accelerating
RevenueProfitEPS
64%71%48%51%32%31%16%12%0.0%−8.2%%%59.6%3.8%3.9%Sep 23Dec 24Jun 26
64%71%48%51%32%31%16%12%0.0%−8.2%%%59.6%3.8%3.9%Sep 23Dec 24Jun 26
ROCE Trailing-twelve-month operating profit (before interest and tax) as a share of average capital employed — total assets minus current liabilities, the standard textbook basis, %.
the return curve, computed quarterly
ROCE
31%27%22%18%13%%14.5%Sep 23Mar 24Dec 24Sep 25Jun 26
31%27%22%18%13%%14.5%Sep 23Dec 24Jun 26
Revenue growth
Rising
latest +59.6% · span +4.8% to +59.6%
Profit growth
Recovering
latest +3.8% · span −2.7% to +65.5%
EPS growth
Recovering
latest +3.9% · span −2.6% to +64.3%
ROCE
Falling
latest 14.5% · span 14.5%–29.8%

Why it matters: when the curves disagree, the per-curve reads above matter more than any single verdict.

Compound annual growth rate (%) Compound annual growth rate over each window, %. Revenue, profit and EPS from fiscal-year figures; share price is the price CAGR over the same spans. A dash = that window is not held, or the base was a loss.
1yr3yr5yr10yr
Revenue+44.0%+20.4%+25.0%+17.2%
Profit+1.9%+9.9%+44.0%
EPS+2.0%+9.9%+43.8%
Share price+4.3%+24.7%+32.9%+21.4%
Revenue YoY (Jun 26)
+78.1%
latest quarter vs a year ago
Profit YoY (Jun 26)
+5.1%
latest quarter vs a year ago
Revenue 10y
17.2%
long-run compound pace
04 · 4-Factor Sector Score

4-Factor Sector Score

39.3/100 — rank 16 of 19 in Hospitals · 87% evidence confidence

Narayana Hrudayalaya Ltd scores 39.3 out of 100 against the 19 companies it is compared with in Hospitals, ranking 16. Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.

The four contributions add to the total exactly: 12.6 + 11.6 + 6.1 + 9 = 39.3. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.

What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.

05 · Revenue

Revenue Revenue is the top line: everything the company billed its customers in the period.

Narayana Hrudayalaya Ltd reported ₹2,684 Cr of revenue in the Jun 26 quarter, +78.1% year on year. That is the 12th straight quarter of year-on-year growth. Over 10 years it has compounded at 17.2% a year. The last full year, FY26, came in at ₹7,896 Cr. The last four reported quarters add to ₹9,073 Cr.

FY26 revenue came in at ₹7,896 Cr (+44.0% on the year), capping 10 years at 17.2% compound. The latest quarter (Jun 26) printed ₹2,684 Cr, +78.1% year on year — the 12th consecutive quarter of year-over-year growth.

FY26 revenue ₹7,896 Cr (+44.0% YoY) Revenue bars, ₹ Cr (left); YoY growth-% line (right). 11-year window. A bar is red when it is lower than the year before.
17.2% a year over 10 years
RevenueYoY growth
8.5k49%6.4k31%4.3k13%2.1k−4.5%0−22%₹ Cr%₹7,89644%FY16FY21FY26
8.5k49%6.4k31%4.3k13%2.1k−4.5%0−22%₹ Cr%₹7,89644%FY16FY21FY26
Jun 26: ₹2,684 Cr (+78.1% YoY) Quarterly revenue bars, ₹ Cr (left); YoY growth-% line (right). Last 12 quarters. A bar is red when it is lower than the quarter before.
12th straight quarter of growth
Revenue (quarterly)YoY growth
2.9k84%2.2k62%1.4k40%72518%0−4.1%₹ Cr%₹2,68478.1%Sep 23Dec 24Jun 26
2.9k84%2.2k62%1.4k40%72518%0−4.1%₹ Cr%₹2,68478.1%Sep 23Dec 24Jun 26

Pace check: the last four quarters averaged +58.9% growth against the decade's 17.2% — the current year is running faster than its own long-run rate.

Acceleration check: trailing-twelve-month revenue grew +59.6% over the last 4 quarters against +33.9%/yr over the last 8 — accelerating; TTM profit +3.8% vs +0.5%/yr — accelerating.

06 · Operating margin

Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.

Narayana Hrudayalaya Ltd's operating margin is 17.0% in the Jun 26 quarter, −5.0 percentage points against the same quarter a year ago. Across 13 fiscal years the operating margin has ranged 7.0% to 24.0%. The current quarter sits inside that band.

The latest quarter's operating margin is 17.0%, −5.0 pp against the same quarter a year ago. Across 13 fiscal years the operating margin has ranged 7.0%–24.0%.

🚨 Why the margin moved: operating margin went −4.9 pp year on year while gross margin went +1.1 pp — the loss came mostly below the gross line: operating leverage, with costs spread over a bigger revenue base.

FY26: 21.0% Operating margin by fiscal year, %, line (left); year-on-year change in the margin, in percentage points, line (right). 13-year window.
within a 7.0–24.0% band over 13 years
operating marginYoY change (pp)
25%12%20%7.2%16%2.0%11%−3.2%5.6%−8.4%%%21%−3%FY14FY20FY26
25%12%20%7.2%16%2.0%11%−3.2%5.6%−8.4%%%21%−3%FY14FY20FY26
Jun 26: 17.0% operating margin (−5.0 pp YoY) Quarterly operating margin, %, line (left); year-on-year change in the margin, in percentage points, line (right). Last 12 quarters. Operating profit as a share of revenue, per quarter.
Operating marginYoY change (pp)
25%1.6%23%−0.5%21%−2.5%18%−4.5%16%−6.6%%%17%−5%Sep 23Dec 24Jun 26
25%1.6%23%−0.5%21%−2.5%18%−4.5%16%−6.6%%%17%−5%Sep 23Dec 24Jun 26
07 · Net profit

Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.

Narayana Hrudayalaya Ltd earned ₹207 Cr of net profit in the Jun 26 quarter, +5.1% year on year. It is the 2nd consecutive quarter of growth. Full-year FY26 profit was ₹806 Cr. The 10-year compound rate is 44.0%. That is 7.7% of the quarter's revenue. The same quarter a year earlier earned ₹197 Cr.

Jun 26 profit was ₹207 Cr, +5.1% year on year — the 2nd consecutive quarter of growth. On the full year, FY26 printed ₹806 Cr (+1.9%), and the 10-year compound rate is 44.0%.

FY26 profit ₹806 Cr (+1.9% YoY) Net profit bars, ₹ Cr (left); YoY growth-% line (right). 11-year window. A bar is red when it is lower than the year before.
44.0% a year over 10 years
Net profitYoY growth
872328%634210%39692%158−26%−80−144%₹ Cr%₹8061.9%FY16FY21FY26
872328%634210%39692%158−26%−80−144%₹ Cr%₹8061.9%FY16FY21FY26
Jun 26: ₹207 Cr (+5.1% YoY) Quarterly net profit bars, ₹ Cr (left); YoY growth-% line (right). Last 12 quarters. A bar is red when it is lower than the quarter before.
2nd straight quarter of growth
Net profit (quarterly)YoY growth
27940%20920%1390.0%70−20%0−40%₹ Cr%₹2075.1%Sep 23Dec 24Jun 26
27940%20920%1390.0%70−20%0−40%₹ Cr%₹2075.1%Sep 23Dec 24Jun 26

Why profit moved: revenue contributed +78.1% and the margin −5.0 pp — the quarter was revenue-led despite a thinner margin.

Pace comparison, last four quarters: profit +3.5% vs revenue +58.9%. Profit is growing slower than sales — costs are eating the growth before it reaches the bottom line.

08 · Cash flow — the router

Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.

Over the last 3 fiscal years 154% of Narayana Hrudayalaya Ltd's reported profit arrived as operating cash — the cash follows the profit. In FY26 that was ₹1,621 Cr of operating cash against ₹806 Cr of profit. After ₹4,184 Cr of capital spending, ₹−2,563 Cr was left as free cash.

FY26: operating cash of ₹1,621 Cr against reported profit of ₹806 Cr, leaving free cash of ₹−2,563 Cr after ₹4,184 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 154% of profit.

Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.

FY26: CFO ₹1,621 Cr vs profit ₹806 Cr Operating cash flow and net profit by fiscal year, ₹ Cr; the line is free cash flow (CFO minus capital spending). 11-year window, annual resolution. FY18 reflects an acquisition year — point shown clipped.
154% of 3-year profit arrived as cash
Operating cashNet profitFree cash
2.0k742−471−1.7k−2.9k₹ Cr₹1,621₹806₹−2,563FY16FY21FY26
2.0k742−471−1.7k−2.9k₹ Cr₹1,621₹806₹−2,563FY16FY21FY26
FY26: CFO = 201% of profit (three-year rate 154%) Operating cash as a share of net profit, per fiscal year, % (line). Dashed line = 100% — every unit of profit arriving as cash; outlier years shown pinned.
Conversion100%
316%258%200%142%84%%201%FY16FY21FY26
316%258%200%142%84%%201%FY16FY21FY26

Why conversion sits at 154%: the cash cycle tightened 26 days between FY21 and FY26 — cash that used to wait in the cycle now reaches the bank sooner.

Router verdict: the bigger cash user is investment — capital spending ran 6.7× depreciation over three years, so the next section's job is to check what that build-out is buying.

09 · Where the cash goes

Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).

Narayana Hrudayalaya Ltd's cash conversion cycle runs −176 days in FY26, down from −150 days in FY21. Capital spending ran ₹6,460 Cr over the last 3 years. At FY26 sales of ₹7,896 Cr each day of that cycle holds about ₹21.6 Cr, so roughly ₹−3,807 Cr sits inside the business at any moment.

FY26: debtors at 30 days, inventory at 42 days — roughly 1.4 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of −176 days, tighter than FY21's −150.

The full loop: cash goes out to suppliers and production on day 0; stock waits 42 days to sell; customers pay about 30 days after that; and suppliers themselves are paid at 248 days — netting out to the −176-day cycle.

In money terms: at FY26 sales of ₹7,896 Cr, each day of the cycle holds about ₹21.6 Cr — so the −176-day loop keeps roughly ₹−3,807 Cr sitting inside the business at any moment.

FY26: a −176-day cash cycle Debtor days, inventory days, payable days and the cash conversion cycle by fiscal year. 13-year window.
−26 days vs FY21
Cash cycleInventory daysDebtor daysPayable days
28215936−87−210days−176d42d30d248dFY14FY17FY20FY23FY26
28215936−87−210days−176d42d30d248dFY14FY20FY26

On the investment side: capital spending of ₹6,460 Cr over the last 3 fiscal years against ₹967 Cr of depreciation — the company is building well ahead of wear-and-tear. Capital work-in-progress stands at ₹292 Cr (FY26) — capacity paid for but not yet earning.

FY26: capex ₹4,184 Cr, work-in-progress ₹292 Cr Capital spending per fiscal year, ₹ Cr (bars); capital work-in-progress, ₹ Cr (line). Quarterly capital-spending history is not held for India — annual is the honest resolution.
a build-out
CapexWork-in-progress
4.5k3.4k2.3k1.1k0₹ Cr₹4,184₹292FY16FY18FY21FY23FY26
4.5k3.4k2.3k1.1k0₹ Cr₹4,184₹292FY16FY21FY26

The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.

10 · Return on capital

Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.

Narayana Hrudayalaya Ltd earns a ROCE of 16% in FY26. That is up from a trough of 2% in FY21. Return on invested capital clears the cost of that capital by +1.0 percentage points, so growth here adds value rather than only size. The wiring behind it is 10.2% net margin on 0.63× asset turns.

FY26 ROCE is 16%, recovered from a FY21 trough of 2% — the full ladder below shows the fall and the climb, undoctored.

Why the return is what it is — the wiring (FY26): 10.2% net margin × 0.63× asset turns × 2.75× balance-sheet leverage ≈ 17.7% on equity. Margin does its share; leverage is a meaningful part of the equation.

The capstone test — ROIC − WACC: 13.0% − 12.0% = a +1.0 pp spread. The 12.0% is a standing assumption for the cost of capital in India, not a per-stock estimate — read the sign and the size of the spread, not the decimals. Positive but thin — value creation with little room for error.

FY26: ROCE 16% Return on capital employed by fiscal year, % (line); ROIC by fiscal year, % (line). 13-year window, dips included. Dashed line = the 12.0% cost of capital used on this page.
the climb back from FY21's 2%
ROCEROIC (annual)WACC
34%26%17%8.3%−0.4%%16%15.9%FY14FY20FY26
34%26%17%8.3%−0.4%%16%15.9%FY14FY20FY26
Q4 FY26: ROCE 11.0% (TTM) vs WACC 12.0% Trailing-twelve-month ROCE and ROIC, per quarter, %; dashed line = the cost of capital. Last 12 quarters, put on a trailing-twelve-month basis and anchored to the annual figure.
ROCE (TTM)ROIC (TTM)WACC
33%27%21%15%9.4%%11%20.7%Q4 FY23Q2 FY25Q4 FY26
33%27%21%15%9.4%%11%20.7%Q4 FY23Q2 FY25Q4 FY26
11 · Debt

Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.

Narayana Hrudayalaya Ltd carries total debt of ₹5,857 Cr against shareholder equity of ₹4,540 Cr as of Mar 26, a debt-to-equity of 1.29. On the annual view that ratio went from 0.49 in FY22 to 1.29 in FY26. Read the returns elsewhere on this page with that leverage in mind.

Mar 26: total debt of ₹5,857 Cr against shareholder equity of ₹4,540 Cr — a debt-to-equity of 1.29. On the annual view, debt-to-equity went from 0.49 (FY22) to 1.29 (FY26). Read the returns on this page with that leverage in mind.

FY26: debt ₹5,857 Cr at 1.29× equity Total debt by fiscal year, ₹ Cr (bars); debt-to-equity, × (line). 5-year window.
Total debtDebt-to-equity
6.3k1.4×4.7k1.1×3.2k0.8×1.6k0.6×00.3×₹ Cr×₹5,8571.29×FY22FY24FY26
6.3k1.4×4.7k1.1×3.2k0.8×1.6k0.6×00.3×₹ Cr×₹5,8571.29×FY22FY24FY26
Mar 26: debt ₹5,857 Cr, debt-to-equity 1.29 Total debt per quarter, ₹ Cr (bars); debt-to-equity, × (line). Last 12 quarters. India reports the full balance sheet half-yearly, so the intervening quarter carries the prior reading forward.
Total debt (quarterly)Debt-to-equity
6.3k1.4×4.7k1.1×3.2k0.8×1.6k0.6×00.3×₹ Cr×₹5,8571.29×Jun 23Sep 24Mar 26
6.3k1.4×4.7k1.1×3.2k0.8×1.6k0.6×00.3×₹ Cr×₹5,8571.29×Jun 23Sep 24Mar 26
12 · Ownership

Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.

No holder of Narayana Hrudayalaya Ltd moved a full percentage point over the last two years — the register is quiet. Promoters moved −0.6 points over the same window, to 63.3%. The register is read on the four disclosed classes only; nothing is inferred between filings.

The register over the last two years — Domestic institutions: +0.8 points over 8 quarters to 9.1%; Promoters: −0.6 points over 8 quarters to 63.3%; Foreign institutions: −0.6 points over 8 quarters to 9.4%.

Fiscal-year ends: promoters −0.6 pts from Mar 24 to Mar 26 Shareholding at each fiscal-year end (March quarter), % of the company. 3 year-ends held.
PromotersForeign inst.Domestic inst.Public
68%52%36%20%4.1%%63.3%10.0%9.1%17.0%Mar 24Mar 25Mar 26
68%52%36%20%4.1%%63.3%10.0%9.1%17.0%Mar 24Mar 25Mar 26
A quiet register: no holder moved a full point in two years Shareholding by holder class, % of the company, quarterly, last 13 quarters.
PromotersForeign inst.Domestic inst.Public
68%52%36%20%3.3%%63.3%9.4%9.1%17.6%Jun 23Dec 24Jun 26
68%52%36%20%3.3%%63.3%9.4%9.1%17.6%Jun 23Dec 24Jun 26
13 · Safety line

Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.

Narayana Hrudayalaya Ltd: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.

The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.

14 · Related companies · Hospitals
CompanyScorePrice stageGrowth & earnings/35Capital efficiency/25Valuation/20Relative strength/20
1KMC Speciality Hospitals (India) Ltd524520 82.1/100Sector-leading setup78% evidence LEADER 30.8/35 Revenue 32.5% · PAT 100% · OPM change 6 pp 83% evidence 20.6/25 ROCE 26% · OPM 31% 76% evidence 11.2/20 P/E 44.5× · PEG — 50% evidence 19.5/20 RS sector 34% · RS bench 44.3% · 1Y 97.6%12 of 12 weeks ahead 100% evidence
Exact sum: 30.8 + 20.6 + 11.2 + 19.5 = 82.1 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence.
2Artemis Medicare Services LtdARTEMISMED 67.9/100Favorable setup96% evidence LEADER 24.4/35 Revenue 15.5% · PAT 24.1% · OPM change 3 pp 88% evidence 12.0/25 ROCE 14.6% · OPM 18% 100% evidence 14.4/20 P/E 44.6× · PEG 1.09 100% evidence 17.1/20 RS sector 8.2% · RS bench 17.1% · 1Y 24.2%11 of 12 weeks ahead 100% evidence
Exact sum: 24.4 + 12 + 14.4 + 17.1 = 67.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
3Sakar Healthcare LtdSAKAR 67.6/100Favorable setup87% evidence LEADER 32.2/35 Revenue 43.9% · PAT 71.4% · OPM change 5 pp 95% evidence 11.0/25 ROCE 12.7% · OPM 29% 95% evidence 6.9/20 P/E 54.6× · PEG — 50% evidence 17.5/20 RS sector 57% · RS bench 68.5% · 1Y 144.1%12 of 12 weeks ahead 100% evidence
Exact sum: 32.2 + 11 + 6.9 + 17.5 = 67.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
4Apollo Hospitals Enterprise LtdAPOLLOHOSP 67.1/100Favorable setup78% evidence LEADER 23.6/35 Revenue 15.8% · PAT 33% · OPM change 1 pp 83% evidence 15.4/25 ROCE 17.9% · OPM 15% 76% evidence 12.6/20 P/E 65.8× · PEG — 50% evidence 15.5/20 RS sector 5.2% · RS bench 13.7% · 1Y 19.9%8 of 12 weeks ahead 100% evidence
Exact sum: 23.6 + 15.4 + 12.6 + 15.5 = 67.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
5Rainbow Childrens Medicare LtdRAINBOW 58.0/100Mixed-positive evidence100% evidence BREAKING OUT 18.0/35 Revenue 18.3% · PAT 12.4% · OPM change 0 pp 100% evidence 17.1/25 ROCE 17.4% · OPM 29% 100% evidence 7.3/20 P/E 54.1× · PEG 2.97 100% evidence 15.6/20 RS sector 4% · RS bench 12.4% · 1Y -2%12 of 12 weeks ahead 100% evidence
Exact sum: 18 + 17.1 + 7.3 + 15.6 = 58 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
6Max Healthcare Institute LtdMAXHEALTH 57.8/100Mixed-positive evidence90% evidence TURNING 25.1/35 Revenue 19.1% · PAT 34% · OPM change 1 pp 88% evidence 15.8/25 ROCE 14.7% · OPM 28% 100% evidence 10.8/20 P/E 72.1× · PEG 1.73 100% evidence 6.1/20 RS sector -7.9% · RS bench 0.1% · 1Y -14.2%2 of 10 weeks ahead 70% evidence
Exact sum: 25.1 + 15.8 + 10.8 + 6.1 = 57.8 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -7.9% and the one-year return is -14.2%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth.
7Kovai Medical Center & Hospital LtdKOVAI 54.6/100Mixed-positive evidence96% evidence FADING 17.8/35 Revenue 15.8% · PAT 16.2% · OPM change -1 pp 88% evidence 21.3/25 ROCE 22.6% · OPM 27% 100% evidence 10.4/20 P/E 26.3× · PEG 1.51 100% evidence 5.1/20 RS sector -7.4% · RS bench 0.2% · 1Y -3.3%4 of 12 weeks ahead 100% evidence
Exact sum: 17.8 + 21.3 + 10.4 + 5.1 = 54.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
8Dr Agarwals Eye Hospital LtdDRAGARWQ 54.3/100Mixed-positive evidence90% evidence ASLEEP 19.6/35 Revenue 18.6% · PAT 27.8% · OPM change -4 pp 88% evidence 16.8/25 ROCE 17.4% · OPM 28% 100% evidence 10.6/20 P/E 34.6× · PEG 1.72 100% evidence 7.3/20 RS sector -4% · RS bench -1% · 1Y 13.4%4 of 7 weeks ahead 70% evidence
Exact sum: 19.6 + 16.8 + 10.6 + 7.3 = 54.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
9Global Health LtdMEDANTA 54.1/100Mixed-positive evidence100% evidence LEADER 12.3/35 Revenue 21.3% · PAT 3.4% · OPM change -2 pp 100% evidence 13.9/25 ROCE 17.1% · OPM 22% 100% evidence 11.3/20 P/E 66× · PEG 1.11 100% evidence 16.6/20 RS sector 4.5% · RS bench 13% · 1Y 6.2%11 of 12 weeks ahead 100% evidence
Exact sum: 12.3 + 13.9 + 11.3 + 16.6 = 54.1 · Decision use: Price leads the evidence: RS versus the benchmark is 13%, but earnings trajectory is weak. Wait for revenue and profit confirmation.
10Indraprastha Medical Corporation LtdINDRAMEDCO 52.2/100Mixed-positive evidence90% evidence ASLEEP 12.4/35 Revenue 9.3% · PAT 13.7% · OPM change -1 pp 88% evidence 18.6/25 ROCE 35.8% · OPM 17% 100% evidence 17.2/20 P/E 18.3× · PEG 0.92 100% evidence 4.0/20 RS sector -8.4% · RS bench -17.3% · 1Y -20.2%0 of 10 weeks ahead 70% evidence
Exact sum: 12.4 + 18.6 + 17.2 + 4 = 52.2 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity.
11Fortis Healthcare LtdFORTIS 50.2/100Mixed-positive evidence78% evidence FADING 23.6/35 Revenue 17.3% · PAT 31.5% · OPM change 1 pp 83% evidence 12.8/25 ROCE 13.4% · OPM 23% 76% evidence 9.0/20 P/E 67.5× · PEG — 50% evidence 4.8/20 RS sector -7.3% · RS bench 0.2% · 1Y 11.8%8 of 12 weeks ahead 100% evidence
Exact sum: 23.6 + 12.8 + 9 + 4.8 = 50.2 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -7.3% and the one-year return is 11.8%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth.
12Yatharth Hospital & Trauma Care Services LtdYATHARTH 48.2/100Mixed-negative evidence78% evidence FADING 19.5/35 Revenue 36.1% · PAT 31.5% · OPM change -2 pp 83% evidence 11.7/25 ROCE 12.4% · OPM 23% 76% evidence 8.8/20 P/E 45× · PEG — 50% evidence 8.2/20 RS sector 0.2% · RS bench 8.1% · 1Y 30.6%11 of 12 weeks ahead 100% evidence
Exact sum: 19.5 + 11.7 + 8.8 + 8.2 = 48.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
13GPT Healthcare LtdGPTHEALTH 47.9/100Mixed-negative evidence70% evidence TURNING 10.3/35 Revenue 16% · PAT -14% · OPM change -2 pp 83% evidence 18.5/25 ROCE 19.9% · OPM 18% 95% evidence 11.2/20 P/E 32.5× · PEG — 15% evidence 7.9/20 RS sector -15.8% · RS bench 17.9% · 1Y 5.9%10 of 10 weeks ahead 70% evidence
Exact sum: 10.3 + 18.5 + 11.2 + 7.9 = 47.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
14Aster DM Quality Care LtdASTERDM 39.4/100Mixed-negative evidence96% evidence LEADER 12.6/35 Revenue 12.2% · PAT -80% · OPM change 1 pp 88% evidence 9.8/25 ROCE 11.4% · OPM 19% 100% evidence 1.5/20 P/E 176× · PEG 3.07 100% evidence 15.5/20 RS sector 10.8% · RS bench 19.6% · 1Y 41.2%11 of 12 weeks ahead 100% evidence
Exact sum: 12.6 + 9.8 + 1.5 + 15.5 = 39.4 · Decision use: Price leads the evidence: RS versus the benchmark is 19.6%, but earnings trajectory is weak. Wait for revenue and profit confirmation.
15Krishna Institute of Medical Sciences LtdKIMS 39.4/100Mixed-negative evidence78% evidence LEADER 10.4/35 Revenue 28.7% · PAT -41.5% · OPM change -6 pp 83% evidence 9.2/25 ROCE 9.3% · OPM 19% 76% evidence 5.5/20 P/E 136× · PEG — 50% evidence 14.3/20 RS sector 3.7% · RS bench 12% · 1Y 5.6%10 of 12 weeks ahead 100% evidence
Exact sum: 10.4 + 9.2 + 5.5 + 14.3 = 39.4 · Decision use: Price leads the evidence: RS versus the benchmark is 12%, but earnings trajectory is weak. Wait for revenue and profit confirmation.
16Narayana Hrudayalaya Ltdthis pageNH 39.3/100Mixed-negative evidence87% evidence TURNING 12.6/35 Revenue 59.6% · PAT 3.8% · OPM change -5 pp 100% evidence 11.6/25 ROCE 15.5% · OPM 17% 100% evidence 6.1/20 P/E 48.1× · PEG 3 65% evidence 9.0/20 RS sector -4.3% · RS bench 9.2% · 1Y 1.9%5 of 10 weeks ahead 70% evidence
Exact sum: 12.6 + 11.6 + 6.1 + 9 = 39.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
17Healthcare Global Enterprises LtdHCG 35.9/100Mixed-negative evidence65% evidence TURNING 13.1/35 Revenue 14.5% · PAT -53.4% · OPM change 1.1 pp 83% evidence 7.4/25 ROCE 8.3% · OPM 19.2% 76% evidence 8.5/20 P/E 349× · PEG — 15% evidence 6.9/20 RS sector -8.1% · RS bench 3.4% · 1Y 18.5%8 of 10 weeks ahead 70% evidence
Exact sum: 13.1 + 7.4 + 8.5 + 6.9 = 35.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
18Shalby LtdSHALBY 30.7/100Adverse evidence69% evidence ASLEEP 15.6/35 Revenue 4.8% · PAT 100% · OPM change 2 pp 62% evidence 2.5/25 ROCE 6.5% · OPM 10% 95% evidence 9.1/20 P/E 46.6× · PEG — 50% evidence 3.5/20 RS sector -28.4% · RS bench -14.9% · 1Y -22.3%6 of 10 weeks ahead 70% evidence
Exact sum: 15.6 + 2.5 + 9.1 + 3.5 = 30.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
19Jupiter Life Line Hospitals LtdJLHL 29.8/100Adverse evidence100% evidence BASING 8.4/35 Revenue 14.7% · PAT -3.1% · OPM change -3 pp 100% evidence 10.5/25 ROCE 14.8% · OPM 19% 100% evidence 6.4/20 P/E 56.9× · PEG 3.44 100% evidence 4.5/20 RS sector -74.8% · RS bench 17.9% · 1Y -77.2%3 of 12 weeks ahead 100% evidence
Exact sum: 8.4 + 10.5 + 6.4 + 4.5 = 29.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.

Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led NIFTY 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.

15 · Frequently asked questions

Frequently asked questions

What is Narayana Hrudayalaya Ltd's share price today?

Narayana Hrudayalaya Ltd trades at ₹2,029, +4.3% over the past year. The company is valued at ₹41,469 Cr. The stock sits at 97% of its 52-week range of ₹1,636–₹2,043, +9.6% versus its 200-day average. On the tape, the price is in a confirmed uptrend, 9 weeks in. — as of 31 July 2026.

What were Narayana Hrudayalaya Ltd's latest quarterly results?

Narayana Hrudayalaya Ltd reported revenue of ₹2,684 Cr and net profit of ₹207 Cr for the Jun 26 quarter. Revenue rose 78.1% and profit rose 5.1% year on year. Earnings per share were ₹10.14. The operating margin was 17.0%, 5.0 pp lower than a year earlier. — as of 31 July 2026.

What is Narayana Hrudayalaya Ltd's revenue?

Narayana Hrudayalaya Ltd reported revenue of ₹2,684 Cr in the Jun 26 quarter, +78.1% year on year. For the full FY26 fiscal year, revenue was ₹7,896 Cr (+44.0%). Over the last 10 years revenue compounded at 17.2% a year. — as of 31 July 2026.

What is Narayana Hrudayalaya Ltd's profit?

Narayana Hrudayalaya Ltd earned ₹207 Cr of net profit in the Jun 26 quarter, +5.1% year on year — the 2nd straight quarter of growth. Full-year FY26 profit was ₹806 Cr. The operating margin ran 17.0% in the latest quarter. — as of 31 July 2026.

What is Narayana Hrudayalaya Ltd's market cap?

Narayana Hrudayalaya Ltd's market capitalisation is ₹41,469 Cr at a share price of ₹2,029. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 31 July 2026.

What is Narayana Hrudayalaya Ltd's P/E ratio?

Narayana Hrudayalaya Ltd trades at a P/E of 48.1×, at the 52nd percentile of its own 10-year range, against a long-run median of 47.0×. This is a comparison with the stock's own history, not a value call — as of 31 July 2026.

Does Narayana Hrudayalaya Ltd pay a dividend?

Yes — Narayana Hrudayalaya Ltd's dividend payout was 11% of profit in FY26, and it recorded a payout in 7 of its last 13 reported fiscal years. This page holds the payout ratio, not a per-share amount. — as of 31 July 2026.

Is Narayana Hrudayalaya Ltd overvalued?

On its own history, Narayana Hrudayalaya Ltd looks mid-range against its own history: its P/E of 48.1× sits at the 52nd percentile of its 10-year range (long-run median 47.0×). That is a percentile read against the stock's own past, not a price opinion or a direction call. — as of 31 July 2026.

Is Narayana Hrudayalaya Ltd growing?

Yes — Narayana Hrudayalaya Ltd is growing: latest-quarter revenue +78.1% year on year, profit +5.1%, and the margin −5.0 pp at 17.0%. The 10-year compound rates are 17.2% (revenue) and 44.0% (profit). The earnings engine currently reads: improving — as of 31 July 2026.

How is Narayana Hrudayalaya Ltd performing?

Narayana Hrudayalaya Ltd is in a confirmed uptrend, 9 weeks in. Its latest quarter's revenue rose 78.1% and profit rose 5.1% year on year. Against the NIFTY 500 it has been behind on a trailing-13-week view for 2 weeks. This describes what the data did, not a rating. — as of 31 July 2026.

What stage is Narayana Hrudayalaya Ltd in?

Mixed — no clean majority across the growth curves, ROCE slipping at 14.5% — the per-curve reads carry the story. The read comes from the last 12 quarters of growth (revenue growth +59.6% latest, profit growth +3.8% latest, eps growth +3.9% latest) plus the ROCE curve, classified by deterministic rules — a trajectory read, not a buy or sell call — as of 31 July 2026.

Is Narayana Hrudayalaya Ltd in an uptrend?

Yes — the price is in a confirmed uptrend (week 9 of stage 2), trading +9.6% versus its 200-day average and at 97% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 31 July 2026.

Is Narayana Hrudayalaya Ltd beating the market?

Not lately — on a trailing-13-week view Narayana Hrudayalaya Ltd is currently behind the NIFTY 500 (2 weeks and counting; last ahead the week of 2026-07-17), the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 10.4 years the stock moved +602% against the NIFTY 500's +276% — ahead of the index over the full window. — as of 31 July 2026.

Will Narayana Hrudayalaya Ltd's share price go up?

This page publishes no price forecast for Narayana Hrudayalaya Ltd. What it measures instead: the share price is ₹2,029, the price is in a confirmed uptrend 9 weeks in. Its P/E of 48.1× sits at the 52nd percentile of its own 10-year range. — as of 31 July 2026.

Who owns Narayana Hrudayalaya Ltd?

Promoters hold 63.3% of Narayana Hrudayalaya Ltd, foreign institutions 9.4%, domestic institutions 9.1% and the public 17.6% (latest quarter). No holder moved a full point over the last two years — the register is quiet. — as of 31 July 2026.

Does Narayana Hrudayalaya Ltd have too much debt?

It carries real leverage — Narayana Hrudayalaya Ltd's debt-to-equity is 1.29, and operating profit covers the interest bill 6×. FY26 borrowings were ₹5,858 Cr against equity of ₹4,537 Cr. Read the returns on this page with that leverage in mind — as of 31 July 2026.

What is Narayana Hrudayalaya Ltd's capex?

Narayana Hrudayalaya Ltd spent ₹6,460 Cr on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY26 alone that was ₹4,184 Cr, with ₹292 Cr in capital work-in-progress — capacity paid for but not yet earning. — as of 31 July 2026.

What is Narayana Hrudayalaya Ltd's cash flow?

Narayana Hrudayalaya Ltd generated ₹1,621 Cr of operating cash flow in FY26 and ₹−2,563 Cr of free cash flow after ₹4,184 Cr of capital spending. Reported profit that year was ₹806 Cr, so operating cash ran ahead of profit. Cash-flow resolution for India is annual. — as of 31 July 2026.

Is Narayana Hrudayalaya Ltd's profit real cash?

Yes — over the last 3 fiscal years, 154% of Narayana Hrudayalaya Ltd's reported profit arrived as operating cash. In FY26, operating cash was ₹1,621 Cr against reported profit of ₹806 Cr. The cash then goes mostly into building capacity. Cash-flow resolution is annual — as of 31 July 2026.

Where is Narayana Hrudayalaya Ltd in its business cycle?

Narayana Hrudayalaya Ltd's FY26 operating margin was 21.0%, against a 13-year band of 7.0%–24.0%: mid-band by its own history — neither the peak that precedes mean-reversion nor the trough that precedes recovery. The latest quarter ran 17.0%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 31 July 2026.

What could break the Narayana Hrudayalaya Ltd story?

Biggest watch item: the price is already 9 weeks into its uptrend — timing risk, not thesis risk. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 31 July 2026.

Is Narayana Hrudayalaya Ltd a stock worth studying right now?

This is not investment advice. The machine read: Narayana Hrudayalaya Ltd's three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it. The sharpest open question: the next one or two quarters of delivery. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 31 July 2026.

Chat with this pageChat with pageChatChatGPTClaudePerplexityGoogle AI